Clinical trial

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

NCT00600587

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention neoadjuvant erlotinib therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention neoadjuvant gemcitabine/carboplatin therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-09-01

PhasePHASE2

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

neoadjuvant erlotinib therapyDRUG

neoadjuvant gemcitabine/carboplatin therapyDRUG

Sponsors & collaborators

Guangdong Provincial People's Hospitallead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00600587 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.